CCEL

Cryo-Cell International, Inc. - 10-Q Summary

Business Context and Reporting Period

Cryo-Cell International, Inc. is engaged in the cellular processing and cryogenic storage of umbilical cord blood stem cells (U-Cord) and has recently launched the C'elle service for menstrual stem cells. This report covers the quarterly period ended February 29, 2008. The company is a smaller reporting company with 11,672,129 shares of common stock outstanding as of April 10, 2008.

Key Financial Metrics

Margins: Cost of sales was 35% of revenue in Q1 2008 (down from 36% in Q1 2007). The company reported an operating loss of $(160,722) for the quarter.

Debt and Liquidity: The company maintains no indebtedness as of April 9, 2008. Liquidity is supported by cash, cash equivalents, and marketable securities totaling approximately $4.25 million. Management anticipates these resources will be sufficient for at least the next 12 months.

Material Changes vs. Prior Period

• Revenue: Remained essentially flat (less than 1% decrease) compared to the prior year. This was driven by a 10% decrease in specimens processed, partially offset by a 14% increase in recurring annual storage fee revenue.
• Net Loss: Significantly improved, decreasing by approximately 69% from $(786,662) to $(247,258).
• Expenses:
  • Marketing, General & Administrative: Decreased 16% to $2,735,240, primarily due to a 44% reduction in consumer advertising.
  • Research & Development: Decreased 67% to $44,700. The prior year included significant costs for placental stem cell services which were postponed indefinitely in April 2007.
  • Cost of Sales: Decreased 5% to $1,445,073 due to fewer specimens processed.
• Other Income: Licensee income decreased to $182,547 from $287,995, largely due to the absence of a $127,440 installment payment from an India license agreement sale recorded in the prior year.

Guidance, Outlook, and Risks

Outlook: Management anticipates capital expenditures of approximately $750,000 over the next twelve months. The company expects cash flows from operations, primarily driven by storage services and new offerings like C'elle, to fund operations. If revenue growth does not materialize, the company may need to reduce expenditures or seek equity/debt financing.

Recent Developments:

• India License: On March 17, 2008, the company entered a definitive license agreement with LifeCell International Private Ltd. for the C'elle program in India, including a $250,000 non-refundable up-front fee and 8% royalty fees.
• Legal Proceedings: The Supreme Court denied PharmaStem's petition for certiorari on March 17, 2008, effectively ending the initial round of patent infringement litigation in the company's favor. A second round of litigation remains stayed pending patent reexamination.
• Corporate Governance: A special shareholder meeting held on March 4, 2008, resulted in the election of a new board of directors following a dispute regarding the 2007 annual meeting.

Risks: Key risks include market acceptance of the new C'elle service, potential increases in government regulation, competition, and the possibility that future tax benefits will not be realized (full valuation allowance on deferred tax assets).

Investor Verification Checklist

• Verify the sustainability of the 44% reduction in consumer advertising and its long-term impact on new customer acquisition.
• Monitor the commercial launch and market acceptance of the C'elle menstrual stem cell service.
• Review the status of the stayed PharmaStem patent litigation and potential impacts on future operations.
• Assess the company's ability to generate positive operating cash flow given the continued net loss and reliance on recurring storage fees.
• Confirm the timeline and payment schedule for the new India license agreement ($100k in Q2 2008, $150k in Q2 2009).